154 related articles for article (PubMed ID: 30133998)
1. Secukinumab reduces plasma oxidative stress in psoriasis: A case-based experience.
Becatti M; Urban ML; Taurisano G; Mannucci A; Barygina V; Pescitelli L; Prignano F; Silvestri E; Taddei N; Lotti T; Fiorillo C; Emmi G
Dermatol Ther; 2018 Sep; 31(5):e12675. PubMed ID: 30133998
[No Abstract] [Full Text] [Related]
2. Secukinumab: a review in moderate to severe plaque psoriasis.
Garnock-Jones KP
Am J Clin Dermatol; 2015 Aug; 16(4):323-330. PubMed ID: 26202871
[TBL] [Abstract][Full Text] [Related]
3. Clinical and economic review of secukinumab for moderate-to-severe plaque psoriasis.
Wong IT; Shojania K; Dutz J; Tsao NW
Expert Rev Pharmacoecon Outcomes Res; 2016; 16(2):153-66. PubMed ID: 26681527
[TBL] [Abstract][Full Text] [Related]
4. Acute Generalized Pustular Psoriasis Treated With the IL-17A Antibody Secukinumab.
Böhner A; Roenneberg S; Eyerich K; Eberlein B; Biedermann T
JAMA Dermatol; 2016 Apr; 152(4):482-4. PubMed ID: 26650014
[No Abstract] [Full Text] [Related]
5. First case of secukinumab successful therapy in a very elderly psoriatic patient.
Ricceri F; Pescitelli L; Lazzeri L; Di Cesare A; Prignano F
Dermatol Ther; 2018 Sep; 31(5):e12668. PubMed ID: 30209856
[No Abstract] [Full Text] [Related]
6. Safety of secukinumab in the treatment of psoriasis.
Blauvelt A
Expert Opin Drug Saf; 2016 Oct; 15(10):1413-20. PubMed ID: 27545070
[TBL] [Abstract][Full Text] [Related]
7. The impact of long-term secukinumab treatment on Epstein-Barr virus and cytomegalovirus loads in patients with psoriasis.
Chiu HY; Chan CC; Tsai TF
Int J Dermatol; 2016 Nov; 55(11):e600-e602. PubMed ID: 27261186
[No Abstract] [Full Text] [Related]
8. Effects of risankizumab in patients with psoriasis previously treated with guselkumab: a case series.
Lin PH; Tsai TF
Eur J Dermatol; 2021 Apr; 31(2):251-252. PubMed ID: 33875411
[No Abstract] [Full Text] [Related]
9. Secukinumab (AIN-457) for the treatment of Psoriasis.
Jaleel T; Elmets C; Weinkle A; Kassira S; Elewski B
Expert Rev Clin Pharmacol; 2016; 9(2):187-202. PubMed ID: 26647300
[TBL] [Abstract][Full Text] [Related]
10. The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study.
Chiu HY; Tsai TF
J Am Acad Dermatol; 2016 Jul; 75(1):224-6. PubMed ID: 27317524
[No Abstract] [Full Text] [Related]
11. Clinical experience of secukinumab in the treatment of erythrodermic psoriasis: a case series.
Weng HJ; Wang TS; Tsai TF
Br J Dermatol; 2018 Jun; 178(6):1439-1440. PubMed ID: 29265175
[No Abstract] [Full Text] [Related]
12. Secukinumab: A positive outcome in a patient with severe psoriasis and HBV-HCV co-infection.
Peccerillo F; Odorici G; Pellacani G; Conti A
Dermatol Ther; 2018 Jul; 31(4):e12601. PubMed ID: 29633448
[No Abstract] [Full Text] [Related]
13. Effects of tumor necrosis factor-α, interleukin-23 and interleukin-17A inhibitors on bodyweight and body mass index in patients with psoriasis.
Takamura S; Takahashi A; Inoue Y; Teraki Y
J Dermatol; 2018 Sep; 45(9):1130-1134. PubMed ID: 30004583
[TBL] [Abstract][Full Text] [Related]
14. Psoriasis therapy and cardiovascular risk factors: a 12-week follow-up study.
Coimbra S; Oliveira H; Reis F; Belo L; Rocha S; Quintanilha A; Figueiredo A; Teixeira F; Castro E; Rocha-Pereira P; Santos-Silva A
Am J Clin Dermatol; 2010 Dec; 11(6):423-32. PubMed ID: 20429617
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of secukinumab in treating moderate to severe plaque psoriasis in two real-world Canadian dermatology clinics: a multicenter retrospective study.
Georgakopoulos JR; Ighani A; Zhou LL; Yeung J
J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e32-e34. PubMed ID: 28695989
[No Abstract] [Full Text] [Related]
16. Secukinumab treatment of moderate to severe plaque psoriasis in routine clinical care: real-life data of prior and concomitant use of psoriasis treatments from the PROSPECT study.
Körber A; Thaçi D; von Kiedrowski R; Bachhuber T; Melzer N; Kasparek T; Kraehn-Senftleben G; Amon U; Augustin M
J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):411-419. PubMed ID: 28960469
[TBL] [Abstract][Full Text] [Related]
17. Risankizumab for severe psoriasis: a case of successful retreatment without induction after 15 months of discontinuation.
Mortato E; Baratta S; Viola R; DE Caro AP; Loconsole F
Ital J Dermatol Venerol; 2024 Apr; 159(2):199-200. PubMed ID: 38650500
[No Abstract] [Full Text] [Related]
18. Secukinumab for plaque psoriasis with ocular comorbidity: a clinical experience.
Cannavò SP; Postorino E; Aragona E; Bartolotta A; Papaianni V; Guarneri C
J Dermatolog Treat; 2018; 29(sup1):9-11. PubMed ID: 30247938
[TBL] [Abstract][Full Text] [Related]
19. [Ustekinumab].
Ortonne JP
Ann Dermatol Venereol; 2011 Dec; 138(12):848-50. PubMed ID: 22137626
[No Abstract] [Full Text] [Related]
20. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.
Blauvelt A; Reich K; Tsai TF; Tyring S; Vanaclocha F; Kingo K; Ziv M; Pinter A; Vender R; Hugot S; You R; Milutinovic M; Thaçi D
J Am Acad Dermatol; 2017 Jan; 76(1):60-69.e9. PubMed ID: 27663079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
